Skip to content

Evaluation of the efficacy of dietary fiber-containing beverage on postprandial blood glucose elevation

Evaluation of the efficacy of dietary fiber-containing beverage on postprandial blood glucose elevation - The effect of dietary fiber-containing beverage on postprandial blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039601
Enrollment
50
Registered
2020-02-25
Start date
2020-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Drinking placebo beverage with eating 150 g of cooked rice Drinking dietary fiber-containing beverage with eating 150 g of cooked rice

Sponsors

KAGOME CO., LTD.
Lead Sponsor
HUMA R&amp
Collaborator
D CORP
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy adults (20 years or older) who do not get treatment or medication 2) Subjects who are normoglycemia or borderline diabetes in previous medical check-ups 3) Subjects whose fasting blood glucose levels are less than 126 mg/dL or blood glucose levels after oral glucose tolerance test (OGTT) are less than 200 mg/dL in the screening test 4) Subjects who do not fit the key exclusion criteria 5) Subjects who are judged healthy by investigators

Exclusion criteria

Exclusion criteria: 1) Subjects who have food allergy to the test meals 2) Subjects who have remarkable hypersensitivity to alcohol 3) Subjects who will get pregnant or breast-feed during the study period 4) Subjects who join other human studies 5) Subjects who are judged unsuitable for this study by investigators

Design outcomes

Primary

MeasureTime frame
Blood glucose levels, the peak value of blood glucose levels, delta blood glucose levels, delta Cmax (the peak value of delta blood glucose levels), IAUC (areas calculated based on the change of delta blood glucose levels)

Countries

Japan

Contacts

Public ContactDaisuke Ochitani

HUMA R&D CORP Clinical Development Division

ochitani@huma-rd.co.jp03-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026